256 related articles for article (PubMed ID: 27626694)
1. Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential.
Kwon JJ; Willy JA; Quirin KA; Wek RC; Korc M; Yin XM; Kota J
Oncotarget; 2016 Nov; 7(44):71635-71650. PubMed ID: 27626694
[TBL] [Abstract][Full Text] [Related]
2. Role of TFEB-driven autophagy regulation in pancreatic cancer treatment.
Klein K; Werner K; Teske C; Schenk M; Giese T; Weitz J; Welsch T
Int J Oncol; 2016 Jul; 49(1):164-72. PubMed ID: 27175909
[TBL] [Abstract][Full Text] [Related]
3. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
4. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
5. MiR-29a inhibited intestinal epithelial cells autophagy partly by decreasing ATG9A in ulcerative colitis.
Xu Y; Yang J; Li F; Lian G; Ouyang M
Anticancer Drugs; 2018 Aug; 29(7):652-659. PubMed ID: 29916896
[TBL] [Abstract][Full Text] [Related]
6. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
Zhou C; Yi C; Yi Y; Qin W; Yan Y; Dong X; Zhang X; Huang Y; Zhang R; Wei J; Ali DW; Michalak M; Chen XZ; Tang J
Mol Cancer; 2020 Jul; 19(1):118. PubMed ID: 32727463
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
[TBL] [Abstract][Full Text] [Related]
8. Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis.
Li C; Zhao Z; Zhou Z; Liu R
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1199-1207. PubMed ID: 27785603
[TBL] [Abstract][Full Text] [Related]
9. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
10. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.
Nagano H; Tomimaru Y; Eguchi H; Hama N; Wada H; Kawamoto K; Kobayashi S; Mori M; Doki Y
Int J Oncol; 2013 Oct; 43(4):1066-72. PubMed ID: 23900458
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
13. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
14. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
16. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
19. miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.
Dey S; Kwon JJ; Liu S; Hodge GA; Taleb S; Zimmers TA; Wan J; Kota J
Mol Cancer Res; 2020 Feb; 18(2):311-323. PubMed ID: 31662451
[TBL] [Abstract][Full Text] [Related]
20. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Zhang L; Yao J; Li W; Zhang C
Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
